New Cholesterol Drug Approval to be Fast-tracked by FDA to Highest Bidder
Regeneron Pharmaceuticals Inc. and Sanofi SA are spending $67.5 million to purchase a voucher that will allow them to get the FDA to fast-track approval of a new class of cholesterol drugs, in hopes of beating a competitor to market.
